摘要
核红系 2 相关因子 (Nrf2) 转录因子/血氧合酶 1 (HO-1) 是重要神经保护反应的关键调节因子,通过驱动各种细胞保护基因的解释来编码抗炎、抗氧化和解毒蛋白.各种研究表明,Nrf2/HO-1 的上调已成为肌萎缩侧索硬化 (ALS) 的潜在治疗方法。肌萎缩侧索硬化是一种运动神经元疾病,其中运动皮层、脑干和皮质脊髓束的上运动神经元和下运动神经元进行性丧失。 Nrf2/HO-1 上调的结果表明,在大脑中,抗氧化能力得到加强。此外,这显示了对肌萎缩侧索硬化中氧化应激的细胞保护作用。一项研究报告了与神经元细胞、少突胶质细胞、小胶质细胞和星形胶质细胞中 Nrf2/HO-1 相关的功能。虽然ALS的发病机制尚不明确,但令人信服。证据表明大脑中的任何功能障碍,如线粒体功能障碍、蛋白质聚集、神经胶质细胞活化、兴奋性毒性和细胞凋亡,这些都会导致类似 ALS 的症状。在这篇综述中,我们主要关注详述 Nrf2/HO-1 的下调,这可能是主要原因,并可能进一步作为 ALS 发展的病理标志。据调查,基于目标的干预措施有限,只能缓解症状,但不能完全治愈疾病。 Nrf2/HO-1 信号通路的失调导致许多生理变化,导致神经系统疾病,包括 ALS。基于上述观点,我们总结了 Nrf2/HO-1 信号在 ALS 中的联合作用,并探索了通过通路调节剂改善疾病的潜在治疗策略。
关键词: 肌萎缩侧索硬化、nrf2/HO-1、少突胶质细胞、小胶质细胞、星形胶质细胞、神经元细胞、细胞凋亡、运动神经元。
Current Molecular Medicine
Title:Targeting Abnormal Nrf2/HO-1 Signaling in Amyotrophic Lateral Sclerosis: Current Insights on Drug Targets and Influences on Neurological Disorders
Volume: 21 Issue: 8
关键词: 肌萎缩侧索硬化、nrf2/HO-1、少突胶质细胞、小胶质细胞、星形胶质细胞、神经元细胞、细胞凋亡、运动神经元。
摘要: The nuclear erythroid 2-related-factor (Nrf2) transcription factor/hemoxygenase 1 (HO-1) is a key regulator of an important neuroprotection response by driving the interpretation of various cytoprotective gene to encode for anti-inflammatory, antioxidant, and detoxifying proteins. Various studies investigated that the upregulation of Nrf2/HO-1 has become the potential therapeutic approach in amyotrophic lateral sclerosis (ALS). Amyotrophic lateral sclerosis is a motor neuron disease in which there is a progressive loss of upper motor neuron and lower motor neurons of the motor cortex, brain stem, and corticospinal tract. A result of this upregulation of Nrf2/HO-1 indicates that in the brain, anti-oxidant capacity is reinforced. Further, this shows a cytoprotective effect against oxidative stress in amyotrophic lateral sclerosis. A study reported functions associated with the Nrf2/HO-1 in the neuronal cell, oligodendrocytes, microglia, and astrocytes. Although ALS's pathogenesis is not yet clear, but it is compelling. The evidence shows any dysfunction in the brain such as mitochondrial dysfunction, protein aggregation, glial cell activation, excitotoxicity, and apoptosis which gives ALS-like symptoms. In this review, we have mainly focused on detailing the downregulation of Nrf2/HO-1, which may be the prime reason and may further serve as a pathological hallmark for ALS development. As surveyed, there are limited targetbased interventions that only provide symptomatic relief but do not cure the disease completely. Dysregulation of the Nrf2/HO-1 signaling pathway leads to many physiological changes contributing to neurological conditions, including ALS. Based on the above view, we summarized the combined role of Nrf2/HO-1 signaling in ALS and explored potential therapeutic strategies for disease improvement through pathway modulators.
Export Options
About this article
Cite this article as:
Targeting Abnormal Nrf2/HO-1 Signaling in Amyotrophic Lateral Sclerosis: Current Insights on Drug Targets and Influences on Neurological Disorders, Current Molecular Medicine 2021; 21 (8) . https://dx.doi.org/10.2174/1566524021666210111104920
DOI https://dx.doi.org/10.2174/1566524021666210111104920 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Shoulder Manifestations of Diabetes Mellitus
Current Diabetes Reviews The Critical Role of Insulin-Like Growth Factor-1 Isoforms in the Physiopathology of Skeletal Muscle
Current Genomics Natural Animal Models of Neurodegenerative Protein Misfolding Diseases
Current Pharmaceutical Design Ascorbic Acid: Its Role in Immune System and Chronic Inflammation Diseases
Mini-Reviews in Medicinal Chemistry “Metabolic Aspects” In Inflammatory Bowel Diseases
Current Drug Delivery Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry New Vectors and Strategies for Cardiovascular Gene Therapy
Current Gene Therapy Syntheses, Transformations and Pharmaceutical Applications of Kynurenic Acid Derivatives
Current Medicinal Chemistry Functional Annotation of Genes Overlapping Copy Number Variants in Autistic Patients: Focus on Axon Pathfinding
Current Genomics Matrix Metalloproteinase-2 and Epidermal Growth Factor are Decreased in Platelets of Alzheimer Patients
Current Alzheimer Research Can Environmentally Relevant Levels of Aluminium Promote the Onset and Progression of Neurodegenerative Diseases?
Current Inorganic Chemistry (Discontinued) Group I Metabotropic Receptor Neuroprotection Requires Akt and Its Substrates that Govern FOXO3a, Bim, and β-Catenin During Oxidative Stress
Current Neurovascular Research Neurotrophic Factors for the Investigation and Treatment of Movement Disorders
Current Medicinal Chemistry - Central Nervous System Agents Commentary (Changes of Synaptic Plasticity in Multiple Sclerosis)
CNS & Neurological Disorders - Drug Targets The Effect of Single and Double Acetylation of Lysine Residues on Structural and Dynamical Features of Human Splicing Factor TDP-43 - A Statistical Ensemble Analysis
Combinatorial Chemistry & High Throughput Screening Denouement of Chemicals on Amyotrophic Lateral Sclerosis: Is Green Chemistry the Answer
Medicinal Chemistry Dysregulation of Neurotrophic and Haematopoietic Growth Factors in Alzheimer’s Disease: From Pathophysiology to Novel Treatment Strategies
Current Alzheimer Research Obesity Pharmacotherapy: Current Perspectives and Future Directions
Current Cardiology Reviews Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology The Implications of Sortilin/Vps10p Domain Receptors in Neurological and Human Diseases
CNS & Neurological Disorders - Drug Targets